Alethia BioTherapeutics
Alethia BioTherapeutics is a clinical-stage Montreal-based biotechnology company developing sotevtamab (AB-16B5), a first-in-class monoclonal antibody targeting sCLU-driven EMT to overcome tumor resistance in metastatic colorectal cancer and NSCLC.
- Company typePrivate
- Founded2002
- HeadquartersMontréal, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Alethia BioTherapeutics does
Alethia BioTherapeutics is a clinical-stage biotechnology company headquartered in Montreal, Quebec, focused on developing monoclonal antibody therapeutics to overcome tumor resistance in cancer treatment. The company was founded in 2002 and operates as Alethia Biotherapeutics ULC, a Canadian unlimited liability company, with a headcount of 11-50 employees.
Alethia's lead asset is sotevtamab (AB-16B5), a monoclonal antibody designed to block secreted clusterin (sCLU)-driven epithelial-mesenchymal transition (EMT), a mechanism that drives tumor progression, metastasis, and resistance to standard therapies. The company's underlying EMT Inhibition Platform is positioned as a first-in-class resistance-targeting approach that restores epithelial architecture, reduces stromal desmoplasia, increases tumor microenvironment permeability, and reestablishes antigen presentation to create a more favorable immune response. Sotevtamab is being advanced as a combination agent intended to complement rather than replace existing chemotherapy regimens.
The company is currently conducting Phase 2 clinical studies in metastatic colorectal cancer (in combination with FOLFOX or FOLFIRINOX) and metastatic non-squamous NSCLC Stage III-IV (in combination with Docetaxel), alongside a completed Phase 1 monotherapy study in progressive metastatic carcinomas. Alethia is pre-revenue and operates under a licensing and royalties revenue model, with planned revenue deriving from drug licensing, co-development partnerships, and eventual product sales. The company maintains an undisclosed strategic co-development partner for upcoming combination therapy studies and relies on scientific publications, conference presentations, and ClinicalTrials.gov listings for visibility.
Alethia BioTherapeutics firmographics
Firmographics- Name
- Alethia BioTherapeutics
- Legal name
- Alethia Biotherapeutics ULC
- Website
- https://alethiabio.com
- Company type
- Private
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Alethia BioTherapeutics is a clinical-stage Montreal-based biotechnology company developing sotevtamab (AB-16B5), a first-in-class monoclonal antibody targeting sCLU-driven EMT to overcome tumor resistance in metastatic colorectal cancer and NSCLC.
- Ownership category
- akta.pro rank
Alethia BioTherapeutics industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
Keywords
Where Alethia BioTherapeutics is headquartered
LocationHeadquarters
- HQ city
- Montréal
- HQ country
- Canada
- HQ region
- North America
Offices1 record
Markets served
Alethia BioTherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Drug Development and Commercialization: As a clinical-stage biotechnology company, Alethia BioTherapeutics is pre-revenue. The company is developing sotevtamab (AB-16B5) through clinical trials with the goal of eventual commercialization as a combination therapy for cancer treatment. Revenue potential exists through drug licensing, co-development partnerships, and eventual product sales.
Go-to-market motion1 record
Marketing channels2 records
Alethia BioTherapeutics product offering
Product offeringCore offering
Alethia BioTherapeutics is a clinical-stage biotechnology company developing sotevtamab (AB-16B5), a monoclonal antibody designed to block sCLU-driven epithelial-mesenchymal transition (EMT) and remodel the immunosuppressive tumor microenvironment. The lead asset is being advanced through Phase 2 clinical studies as a combination therapy in metastatic colorectal cancer and non-small cell lung cancer (NSCLC).
Product overview
Alethia BioTherapeutics is a clinical-stage biotechnology company developing a single lead asset, sotevtamab (AB-16B5), supported by its EMT (epithelial-mesenchymal transition) inhibition platform. Sotevtamab is a monoclonal antibody designed to overcome tumor resistance by blocking sCLU-driven EMT and reprogramming the immunosuppressive tumor microenvironment. The platform is positioned as a first-in-class resistance-targeting approach with a combination-driven clinical strategy. The company is advancing sotevtamab through multiple Phase 2 clinical studies across metastatic colorectal cancer and non-small cell lung cancer (NSCLC) indications, both as monotherapy and in combination with standard chemotherapies (FOLFOX, FOLFIRINOX, Docetaxel).
Differentiator
Problem solved
Functional benefit
Products and services
- Sotevtamab (AB-16B5)
Companies that use Alethia BioTherapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Alethia BioTherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Alethia BioTherapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Undisclosed PartnercoreAlethia BioTherapeutics has an undisclosed partner for combination therapy development in the metastatic colorectal cancer program (AB-16B5-204). The partnership involves combination treatment with FOLFOX or FOLFIRINOX chemotherapy regimens, though specific partner details are not publicly disclosed.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
Alethia BioTherapeutics competitors and assessment
Company assessmentBroad incumbents
- Merck & Co. Global oncology leader (Keytruda franchise) actively seeking combination partners to extend chemo and immunotherapy efficacy. Represents a plausible partnership or acquirer profile for a Phase 2 combination-enabled mAb asset.
- Genentech (Roche): Large oncology pharma leader with deep monoclonal antibody franchise (e.g., bevacizumab, atezolizumab). Represents the type of strategic acquirer or combination partner interested in differentiated TME-modulating mechanisms like sotevtamab.
Emerging players
- CytomX Therapeutics: Clinical-stage oncology biotech developing Probody therapeutics — masked antibodies activated in the TME. Comparable platform-based approach to engineering biologics that preferentially act within the tumor microenvironment.
- Bolt Biotherapeutics: Clinical-stage oncology biotech developing immune-stimulating antibody conjugates that target the tumor microenvironment. Comparable as a small-cap, clinical-stage oncology platform company pursuing TME-modulating approaches with biologics.
- Molecular Partners: Clinical-stage biotech developing DARPins and other novel protein therapeutics for oncology. Comparable as a small clinical-stage company building a biologics platform with multiple oncology programs in mid-stage development.
- Pieris Pharmaceuticals: Clinical-stage biotech developing Anticalin protein therapeutics for oncology and respiratory diseases. Comparable in size, modality (engineered protein biologics), and clinical-stage profile with partnership-driven development.
Direct peers
- Mereo BioPharma: Clinical-stage biotech developing biologics and small molecules for oncology and rare diseases. Comparable to Alethia in size, clinical-stage profile, and combination-partnership-driven commercialization model.
- Trillium Therapeutics: Canadian clinical-stage biotech that developed biologic oncology therapeutics and was acquired by Pfizer in 2022. Highly comparable to Alethia as a small, Canada-based clinical-stage oncology biotech advancing novel biologics through mid-stage trials.
- MacroGenics: Clinical-stage biotech developing monoclonal antibody therapeutics for oncology, including checkpoint inhibitors and bispecifics. Closely comparable technology modality (mAbs) and oncology focus, with multiple mid-stage programs and partnership history.
Regional players
- Akeso Inc. China-based clinical-stage biotech developing a large portfolio of novel monoclonal antibodies for oncology, including TME-targeting assets. Comparable modality and clinical-stage profile, though primarily operating in the Chinese market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Alethia BioTherapeutics social profiles
Digital presenceAlethia BioTherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alethia BioTherapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Alethia BioTherapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alethia BioTherapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alethia BioTherapeutics
What does Alethia BioTherapeutics do?
Alethia BioTherapeutics is a clinical-stage biotechnology company developing sotevtamab (AB-16B5), a monoclonal antibody designed to block sCLU-driven epithelial-mesenchymal transition (EMT) and remodel the immunosuppressive tumor microenvironment. The lead asset is being advanced through Phase 2 clinical studies as a combination therapy in metastatic colorectal cancer and non-small cell lung cancer (NSCLC).
Is Alethia BioTherapeutics a public or private company?
Alethia BioTherapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alethia BioTherapeutics founded?
Alethia BioTherapeutics was founded in 2002. It employs 11 to 50 people.
Where is Alethia BioTherapeutics based?
Alethia BioTherapeutics is headquartered in Montréal, Canada, in the North America region.
How does Alethia BioTherapeutics make money?
One revenue line is on record: drug Development and Commercialization.
Who are Alethia BioTherapeutics's main competitors?
Broad incumbents on record are Merck & Co. and Genentech (Roche). Emerging players are CytomX Therapeutics, Bolt Biotherapeutics, Molecular Partners and Pieris Pharmaceuticals. Direct peers are Mereo BioPharma, Trillium Therapeutics and MacroGenics. Akeso Inc. is listed as a regional player.
Does Alethia BioTherapeutics have an API?
No public API is recorded for Alethia BioTherapeutics.
What industry is Alethia BioTherapeutics in?
Alethia BioTherapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.